Selective Therapeutic for C. diff Infection

Bookmark/Download	Download as PDF
Track Code	2018-RAMA-68247
Categories	Pharmaceuticals
Keywords	Antibiotic-associated Diarrhea Antibiotics C. diff Clostridium difficile Infection Fidaxomicin Pharmaceuticals Vancomycin
Public Abstract	Researchers at Purdue University have developed new drug candidates that promise to be effective in the treatment of Clostridium difficile Infection (CDI). This infection is the most common bacterial cause of antibiotic-associated diarrhea (AAD) with an estimated 500,000 cases annually resulting in approximately 29,000 deaths in the United States alone. Many patients treated with fidaxomicin, the only antibiotic approved for CDI in the past 40 years, experience a recurrence of CDI. The Purdue drug cures mice of CDI and prevents recurrence. The lead molecule is not toxic in mice or a human cell line. Further, this new therapeutic is selective for C. diff; it does not inhibit growth in representative species of normal gut microflora. Advantages: -New class of molecules against C. diff -Does not inhibit growth of normal gut microflora -Non-toxic in human cells and mice Potential Applications: -C. diff treatment -Therapy for antibiotic-associated diarrhea and colitis
People	Ramachandran, P V (Project leader) Seleem, Mohamed
Intellectual Property	Application Date Feb 3, 2023 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Feb 3, 2022 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Aug 22, 2019 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Aug 27, 2018 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org